Halozyme Therapeutics (HALO) Other Non-Current Liabilities (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Other Non-Current Liabilities data on file, last reported at $106.4 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 88.62% year-over-year to $106.4 million in Q1 2026; TTM through Mar 2026 was $106.4 million, a 88.62% increase from a year earlier, with the FY2025 full-year figure at $113.9 million, up 107.94% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $106.4 million, down from $113.9 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for HALO reached as high as $130.0 million in Q2 2022 and fell as low as $171000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $50.6 million across 5 years, with a median of $37.7 million in 2023.
• Across the five-year window, Other Non-Current Liabilities plunged 93.91% in 2022 and soared 17194.15% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $15.5 million in 2022, then surged by 143.8% to $37.7 million in 2023, then soared by 45.17% to $54.8 million in 2024, then jumped by 107.94% to $113.9 million in 2025, then decreased by 6.51% to $106.4 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $106.4 million in Q1 2026, $113.9 million in Q4 2025, and $71.8 million in Q3 2025.